Loading organizations...
§ Venture Capital · Seoul, Seoul-t'ukpyolsi, South Korea
Hybrid venture capital and private equity firm investing South Korean capital in overseas biotech and tech startups.
InHarv Partners is a Seoul, South Korea-based hybrid venture capital and private equity firm that raises domestic capital for investment in cutting-edge overseas technology startups. The firm strategically links these international startups to Korean industries, serving as a bridge between South Korean capital and global tech innovation. While specific AUM or employee figures are not publicly disclosed, InHarv Partners has co-invested in significant funding rounds, including a $50 million cancer research financing. Its portfolio involvement includes biotech companies like Verseau Therapeutics and Presage Biosciences, often co-investing with firms like 20/20 HealthCare Partners and The Mark Foundation for Cancer Research. Founded in 2015 by Jong Chang, formerly a lead partner at Booz Allen Hamilton, he also serves on portfolio company boards.
InHarv Partners has 1 tracked investment across 1 company. The latest tracked deal is $13.0M Other Equity in Presage Biosciences in March 2021.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Mar 2, 2021 | Presage Biosciences | $13.0M Other Equity | — | Bristol Myers Squibb, Labcorp, Takeda Ventures |